Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 as Adjunct in Major Depressive Disorder (RENAISSANCE 3)
NCT01197508Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Primary completion
- Jan 2012
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of dexmecamylamine in major depressive disorder (MDD), sponsored by AstraZeneca. Started Sep 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01197508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197508.